MYC and cancer: Of these, 10 pathways were seen to be differentially expressed between E1 and E3 consistently in all 3 cohorts (encompassing 22% of unique enriched pathways across cohorts, p < 0.05, Fisher’s Exact Test; Fig. 2c), with crucial functions in cell growth (E2F and MYC target pathways) and a reduced hormone response (androgen and estrogen response pathways), indicating aggressive cancer growth and reduced sensitivity to hormone signaling in the E3 subtype.